A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation


Type carcinoma: NSCLC met mutatie
Stadium: IV
Mutatie: KRAS G12C
Lijn: 2e na triple therapie
Site: Erasmus MC


Website: https://-/


  • Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with
    KRAS G12C mutation and known PD-L1 Tumor Proportion Score (TPS) score.
  • Unresectable or metastatic disease.
  • Not a candidate for definitive therapy (e.g., chemoradiation for locally advanced
  • PD-L1 >50%


  • Prior systemic treatment for locally advanced or metastatic NSCLC including
    chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS
    G12C mutation (e.g., AMG 510).
  • Radiation to the lung >30 Gy within 6 months prior to the first dose of study
  • Active brain metastases. Patients are eligible if brain metastases are adequately
    treated and patients are neurologically stable (except for residual signs or symptoms
    related to the central nervous system [CNS] treatment) for at least 2 weeks prior to
    the first dose of study treatment without the use of corticosteroids or are on a stable or
    decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
  • Carcinomatous meningitis.

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:


An open-label Phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) with a PD-L1 expression <1% or a PD-L1 expression ≥1% and an STK11 co-mutation